Section VI — Questions
PT-141: Frequently Asked Questions
Direct answers from the published record — definitional, mechanistic, and dosing questions, cited where they make a quantitative claim.
What does the PT-141 peptide do?
PT-141 (bremelanotide) is a synthetic melanocortin MC3R/MC4R receptor agonist that acts centrally, in the brain, to influence sexual desire and arousal [1]. It is FDA-approved for only one use — HSDD (distressing low sexual desire) in premenopausal women — at a 1.75 mg subcutaneous as-needed dose [3] [11]. It works on the wiring of desire, not on blood flow.
What is PT-141?
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide (a ring of seven amino acids) analogue of alpha-MSH that activates central melanocortin MC3R/MC4R receptors to influence sexual desire and arousal [1]. It is a real, approved prescription drug whose licence covers a single indication [11].
What is PT-141 peptide?
A cyclic seven-amino-acid melanocortin-receptor-agonist peptide — bremelanotide — structurally related to the natural brain peptide alpha-MSH and studied for its central effects on sexual desire [1]. Its cyclic ring makes it sturdier than linear melanocortin peptides, which is part of why it can be dosed by injection [1].
What is PT-141 used for?
Its single FDA-approved use is acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women [3] [11]. All other uses — in men, for erectile dysfunction, in postmenopausal women, for sexual 'performance' — are off-label or investigational and are not supported by the approval [11].
Is PT-141 the same as bremelanotide?
Yes. PT-141 is the development and research designation; bremelanotide is the international nonproprietary name (INN) of the same melanocortin receptor agonist [3]. The two names point to one compound, approved under NDA 210557 in June 2019 [11].
What is bremelanotide?
Bremelanotide is the approved-drug name for PT-141, a melanocortin MC3R/MC4R agonist approved in June 2019 for HSDD in premenopausal women at a 1.75 mg subcutaneous as-needed dose [11]. It is the same molecule the research literature calls PT-141 [3].
How does PT-141 work?
It activates central melanocortin receptors — chiefly MC4R — in hypothalamic and limbic circuits, engaging dopaminergic pathways tied to sexual motivation, rather than acting on vascular blood flow like a PDE-5 inhibitor [1]. In a human fMRI study, this raised sexual desire for up to 24 hours and shifted brain processing of erotic stimuli [5].
What receptors does PT-141 act on?
Mainly the melanocortin 4 receptor (MC4R) and, secondarily, the melanocortin 3 receptor (MC3R), both concentrated in the central nervous system [1]. These are the brain-side members of a five-receptor melanocortin family, which is why PT-141's primary action is central rather than vascular [1].
Does PT-141 work through the brain or through blood flow?
Through the brain. PT-141 acts centrally on hypothalamic melanocortin circuits governing sexual motivation, unlike PDE-5 inhibitors, which act peripherally on vascular smooth muscle to increase erectile blood flow [1]. The two mechanisms are entirely distinct — desire versus plumbing [11].
What is a melanocortin receptor agonist?
A compound that activates one or more of the five melanocortin receptors (MC1R-MC5R) [1]. PT-141 is a synthetic analogue of alpha-MSH that targets the central MC3R/MC4R subtypes, which is what places its action in the brain's desire circuitry rather than in skin or blood vessels [1].
Does PT-141 increase testosterone?
No. PT-141 does not act via the hypothalamic-pituitary-gonadal axis and does not directly raise testosterone; it works through central melanocortin signalling, not hormone production [1]. The desire effect is a matter of brain circuitry, not endocrine output [11].
How is PT-141 different from PDE-5 inhibitors?
PT-141 is a central melanocortin agonist that modulates sexual desire in the brain; PDE-5 inhibitors are peripheral vasodilators that improve erectile blood flow [1]. The mechanisms are entirely distinct, which is why PT-141 was pursued for low desire — a problem a blood-flow drug cannot reach [11].
Why does PT-141 cause nausea?
Nausea is the most common adverse event — about 40% over long-term use — and a leading reason participants discontinued [4]. It is linked to central melanocortin signalling reaching circuits beyond desire, and in studies it was dose- and timing-related, which is why injection timing has been examined as a mitigation [3] [4].
Does PT-141 cause skin darkening or hyperpigmentation?
Focal darkening of skin, gums, and breasts is reported with repeated frequent dosing and is attributed to MC1R activation — the pigment receptor in the same melanocortin family [11]. It is a documented, mechanism-consistent effect that researchers commonly note, not a rumour [11].
Does PT-141 cause weight loss?
Because MC4R is also expressed in appetite circuits, Phase 1 obesity research showed reduced caloric intake and body weight at high-frequency research dosing (up to 2.5 mg, up to three times daily for 15 days) [11]. This is a pharmacological observation, not an approved use [11].
How often can you take PT-141?
The prescribing information specifies no more than one dose per 24 hours and no more than 8 doses per month [11]. This is reported as a label limit, not a recommendation to self-administer; frequency drives both the tolerability burden and the pigment effect [11].
What is the PT-141 dosage?
In the RECONNECT trials and the label, the studied dose was 1.75 mg subcutaneously, as needed [3] [11]. Earlier research used 0.75-1.75 mg subcutaneous in women and higher intranasal doses in men [1]. These are reported as findings only, not as guidance [11].
How much PT-141 should I take?
This site reports trial and label doses (1.75 mg subcutaneous as needed) as research findings, not as a protocol to follow [11]. It is not medical advice and recommends no dose for any individual [3].
How much PT-141 to inject?
The approved subcutaneous dose studied was 1.75 mg as needed, taken at least 45 minutes before anticipated activity [11]. This is recorded as a study and label parameter, not as guidance to inject anything [11].
How do you reconstitute PT-141?
The approved product is a prefilled subcutaneous autoinjector, not a reconstituted powder [11]. Material sold as 'PT-141 research chemical' is laboratory material only; this site describes how the medicine is prepared, not a how-to for unregulated material [11].
How do you take PT-141?
In the approved use it is a subcutaneous injection taken as needed before anticipated sexual activity [11]. Early development also tested intranasal and intravenous routes, since discontinued in favour of the subcutaneous route [11]. Reported as a study and label parameter, not as instruction [1].
What is the approved bremelanotide dose?
1.75 mg subcutaneously, as needed, at least 45 minutes before anticipated sexual activity, with no more than one dose per 24 hours and no more than 8 doses per month, per the US prescribing information [11]. Stated as the label figure, not as a recommendation [11].